Study shows self-monitoring tools make a difference, ResMed says

Tuesday, October 25, 2016

LOS ANGELES – More than 87% of CPAP users were compliant with their therapy when they used ResMed’s myAir and were monitored with AirView, according to the results of a study that will be presented at the CHEST annual meeting on Oct. 26. That’s compared to 70% of PAP users who were compliant when they were only monitored with AirView. “This new study shows that online self-monitoring tools engage patients and significantly improve their compliance and adherence to treatment,” said Adam Benjafield, ResMed’s medical director. The results of the observational study were based on 128,000 people with sleep apnea.  myAir, which is available on the web and via iPhone app to patients using ResMed’s Air10 devices, allows users to track the progress of their therapy between visits to their clinicians, including their daily sleep scores, details on four key treatment metrics and personalized coaching tips. Without wireless monitoring, CPAP adherence can be as low as 50%, according to ResMed.